𝛼SK or Searchbullish
Pharmarise HDS | 2796 FY2026/5 Q4 Follow-Up
SUMMARY
- In FY2026/5, operating profit increased 233.5% YoY, while net profit returned to the black.
- The core Dispensing pharmacy business also posted a sharp increase in profit, indicating that the benefits of post-merger integration (PMI) and improvements at existing stores are beginning to translate into earnings alongside the scale expansion achieved through M&A.
- Going forward, SIR believes there is substantial room for valuation to normalize provided the Company continues to deliver profit growth and the earnings recovery proves sustainable.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Pharmarise HDS | 2796 FY2026/5 Q4 Follow-Up01 Sep 2026
x